nodes	percent_of_prediction	percent_of_DWPC	metapath
Lisuride—CYP2D6—breast cancer	0.159	0.538	CbGaD
Lisuride—CYP3A4—breast cancer	0.136	0.462	CbGaD
Lisuride—HTR2B—Raloxifene—breast cancer	0.0898	0.241	CbGbCtD
Lisuride—CYP3A4—Exemestane—breast cancer	0.0291	0.0781	CbGbCtD
Lisuride—CYP2D6—Idarubicin—breast cancer	0.0263	0.0706	CbGbCtD
Lisuride—CYP3A4—Letrozole—breast cancer	0.0247	0.0664	CbGbCtD
Lisuride—CYP3A4—Anastrozole—breast cancer	0.022	0.0592	CbGbCtD
Lisuride—CYP3A4—Toremifene—breast cancer	0.0202	0.0542	CbGbCtD
Lisuride—CYP3A4—Fulvestrant—breast cancer	0.0187	0.0504	CbGbCtD
Lisuride—CYP3A4—Thiotepa—breast cancer	0.0167	0.0449	CbGbCtD
Lisuride—CYP3A4—Ixabepilone—breast cancer	0.0153	0.041	CbGbCtD
Lisuride—CYP3A4—Lapatinib—breast cancer	0.0147	0.0395	CbGbCtD
Lisuride—CYP2D6—Vinorelbine—breast cancer	0.0128	0.0345	CbGbCtD
Lisuride—CYP2D6—Tamoxifen—breast cancer	0.0116	0.0311	CbGbCtD
Lisuride—CYP3A4—Raloxifene—breast cancer	0.0111	0.0299	CbGbCtD
Lisuride—CYP3A4—Vinorelbine—breast cancer	0.00816	0.0219	CbGbCtD
Lisuride—CYP2D6—Vinblastine—breast cancer	0.00791	0.0212	CbGbCtD
Lisuride—CYP3A4—Tamoxifen—breast cancer	0.00736	0.0198	CbGbCtD
Lisuride—CYP3A4—Mitoxantrone—breast cancer	0.00718	0.0193	CbGbCtD
Lisuride—CYP3A4—Paclitaxel—breast cancer	0.00573	0.0154	CbGbCtD
Lisuride—CYP3A4—Irinotecan—breast cancer	0.00565	0.0152	CbGbCtD
Lisuride—CYP3A4—Vinblastine—breast cancer	0.00503	0.0135	CbGbCtD
Lisuride—CYP2D6—Doxorubicin—breast cancer	0.00486	0.0131	CbGbCtD
Lisuride—CYP3A4—Docetaxel—breast cancer	0.00414	0.0111	CbGbCtD
Lisuride—CYP3A4—Doxorubicin—breast cancer	0.00309	0.0083	CbGbCtD
Lisuride—ADRA1D—epithelium—breast cancer	0.000487	0.0412	CbGeAlD
Lisuride—DRD5—female reproductive system—breast cancer	0.000451	0.0381	CbGeAlD
Lisuride—Ergonovine—CYP3A4—breast cancer	0.000413	0.165	CrCbGaD
Lisuride—DRD5—female gonad—breast cancer	0.00041	0.0347	CbGeAlD
Lisuride—ADRA2C—nipple—breast cancer	0.000395	0.0334	CbGeAlD
Lisuride—DRD5—endocrine gland—breast cancer	0.000381	0.0323	CbGeAlD
Lisuride—ADRA1D—female reproductive system—breast cancer	0.000361	0.0306	CbGeAlD
Lisuride—Methylergometrine—CYP3A4—breast cancer	0.000361	0.144	CrCbGaD
Lisuride—Cabergoline—CYP3A4—breast cancer	0.000361	0.144	CrCbGaD
Lisuride—Ergonovine—ABCB1—breast cancer	0.000343	0.137	CrCbGaD
Lisuride—Pergolide—CYP2D6—breast cancer	0.000325	0.13	CrCbGaD
Lisuride—HTR2B—skin of body—breast cancer	0.000322	0.0272	CbGeAlD
Lisuride—ADRA2A—nipple—breast cancer	0.000316	0.0267	CbGeAlD
Lisuride—ADRA1D—endocrine gland—breast cancer	0.000306	0.0259	CbGeAlD
Lisuride—HTR2B—endometrium—breast cancer	0.000303	0.0257	CbGeAlD
Lisuride—ADRB1—adipose tissue—breast cancer	0.000286	0.0242	CbGeAlD
Lisuride—HTR2B—uterus—breast cancer	0.00028	0.0236	CbGeAlD
Lisuride—HTR1B—female reproductive system—breast cancer	0.000279	0.0236	CbGeAlD
Lisuride—Pergolide—CYP3A4—breast cancer	0.000279	0.111	CrCbGaD
Lisuride—HTR2B—adipose tissue—breast cancer	0.000273	0.0231	CbGeAlD
Lisuride—HTR1D—female reproductive system—breast cancer	0.00027	0.0229	CbGeAlD
Lisuride—HTR2C—female reproductive system—breast cancer	0.000268	0.0226	CbGeAlD
Lisuride—ADRB1—female reproductive system—breast cancer	0.000263	0.0222	CbGeAlD
Lisuride—HTR2B—female reproductive system—breast cancer	0.000251	0.0213	CbGeAlD
Lisuride—HTR2B—adrenal gland—breast cancer	0.000245	0.0207	CbGeAlD
Lisuride—ADRA2C—endometrium—breast cancer	0.000239	0.0202	CbGeAlD
Lisuride—HTR1B—endocrine gland—breast cancer	0.000236	0.02	CbGeAlD
Lisuride—Ergotamine—CYP3A4—breast cancer	0.000232	0.0927	CrCbGaD
Lisuride—DRD2—pituitary gland—breast cancer	0.000222	0.0188	CbGeAlD
Lisuride—ADRB1—endocrine gland—breast cancer	0.000222	0.0188	CbGeAlD
Lisuride—HTR2A—embryo—breast cancer	0.000221	0.0187	CbGeAlD
Lisuride—ADRA2C—uterus—breast cancer	0.00022	0.0186	CbGeAlD
Lisuride—HTR1A—adrenal gland—breast cancer	0.00022	0.0186	CbGeAlD
Lisuride—ADRA2C—pituitary gland—breast cancer	0.000216	0.0183	CbGeAlD
Lisuride—ADRA2C—adipose tissue—breast cancer	0.000215	0.0182	CbGeAlD
Lisuride—Ergotamine—ABCB1—breast cancer	0.000193	0.0772	CrCbGaD
Lisuride—ADRA2C—adrenal gland—breast cancer	0.000193	0.0163	CbGeAlD
Lisuride—HTR1A—endocrine gland—breast cancer	0.000191	0.0161	CbGeAlD
Lisuride—ADRA2A—endometrium—breast cancer	0.000191	0.0161	CbGeAlD
Lisuride—HTR2A—epithelium—breast cancer	0.000181	0.0153	CbGeAlD
Lisuride—Confusional state—Fluorouracil—breast cancer	0.000181	0.000953	CcSEcCtD
Lisuride—Dizziness—Vinblastine—breast cancer	0.00018	0.000953	CcSEcCtD
Lisuride—ADRA2C—female gonad—breast cancer	0.00018	0.0152	CbGeAlD
Lisuride—Oedema peripheral—Docetaxel—breast cancer	0.000179	0.000946	CcSEcCtD
Lisuride—Nervous system disorder—Gemcitabine—breast cancer	0.000179	0.000943	CcSEcCtD
Lisuride—Feeling abnormal—Thiotepa—breast cancer	0.000178	0.000942	CcSEcCtD
Lisuride—Anorexia—Mitoxantrone—breast cancer	0.000178	0.000941	CcSEcCtD
Lisuride—Anorexia—Irinotecan—breast cancer	0.000178	0.000941	CcSEcCtD
Lisuride—Infection—Fluorouracil—breast cancer	0.000178	0.000939	CcSEcCtD
Lisuride—Hyperhidrosis—Gemcitabine—breast cancer	0.000176	0.00093	CcSEcCtD
Lisuride—Nervous system disorder—Fluorouracil—breast cancer	0.000176	0.000927	CcSEcCtD
Lisuride—ADRA2A—uterus—breast cancer	0.000176	0.0149	CbGeAlD
Lisuride—Dizziness—Tamoxifen—breast cancer	0.000175	0.000925	CcSEcCtD
Lisuride—Tachycardia—Fluorouracil—breast cancer	0.000175	0.000923	CcSEcCtD
Lisuride—Anorexia—Gemcitabine—breast cancer	0.000174	0.000917	CcSEcCtD
Lisuride—Oedema peripheral—Capecitabine—breast cancer	0.000173	0.000916	CcSEcCtD
Lisuride—Vomiting—Vinblastine—breast cancer	0.000173	0.000916	CcSEcCtD
Lisuride—ADRA2A—pituitary gland—breast cancer	0.000172	0.0146	CbGeAlD
Lisuride—DRD2—endocrine gland—breast cancer	0.000172	0.0146	CbGeAlD
Lisuride—ADRA2A—adipose tissue—breast cancer	0.000172	0.0145	CbGeAlD
Lisuride—Headache—Vinblastine—breast cancer	0.000171	0.000902	CcSEcCtD
Lisuride—Anorexia—Fluorouracil—breast cancer	0.000171	0.000901	CcSEcCtD
Lisuride—Insomnia—Irinotecan—breast cancer	0.000169	0.000893	CcSEcCtD
Lisuride—Cardiac disorder—Docetaxel—breast cancer	0.000169	0.000892	CcSEcCtD
Lisuride—Vomiting—Tamoxifen—breast cancer	0.000168	0.00089	CcSEcCtD
Lisuride—Vertigo—Paclitaxel—breast cancer	0.000168	0.000886	CcSEcCtD
Lisuride—Syncope—Paclitaxel—breast cancer	0.000168	0.000885	CcSEcCtD
Lisuride—Dizziness—Goserelin—breast cancer	0.000167	0.000884	CcSEcCtD
Lisuride—Dyspnoea—Mitoxantrone—breast cancer	0.000167	0.00088	CcSEcCtD
Lisuride—Dyspnoea—Irinotecan—breast cancer	0.000167	0.00088	CcSEcCtD
Lisuride—Somnolence—Mitoxantrone—breast cancer	0.000166	0.000878	CcSEcCtD
Lisuride—Somnolence—Irinotecan—breast cancer	0.000166	0.000878	CcSEcCtD
Lisuride—Headache—Tamoxifen—breast cancer	0.000166	0.000877	CcSEcCtD
Lisuride—Palpitations—Paclitaxel—breast cancer	0.000165	0.000872	CcSEcCtD
Lisuride—Angiopathy—Docetaxel—breast cancer	0.000165	0.000872	CcSEcCtD
Lisuride—Vomiting—Melphalan—breast cancer	0.000165	0.000871	CcSEcCtD
Lisuride—Dehydration—Epirubicin—breast cancer	0.000165	0.000871	CcSEcCtD
Lisuride—Insomnia—Gemcitabine—breast cancer	0.000165	0.00087	CcSEcCtD
Lisuride—Immune system disorder—Docetaxel—breast cancer	0.000164	0.000868	CcSEcCtD
Lisuride—Mediastinal disorder—Docetaxel—breast cancer	0.000164	0.000866	CcSEcCtD
Lisuride—Cardiac disorder—Capecitabine—breast cancer	0.000163	0.000863	CcSEcCtD
Lisuride—Cough—Paclitaxel—breast cancer	0.000163	0.000861	CcSEcCtD
Lisuride—Asthenia—Vinorelbine—breast cancer	0.000163	0.000859	CcSEcCtD
Lisuride—Decreased appetite—Irinotecan—breast cancer	0.000163	0.000858	CcSEcCtD
Lisuride—Decreased appetite—Mitoxantrone—breast cancer	0.000163	0.000858	CcSEcCtD
Lisuride—Dyspnoea—Gemcitabine—breast cancer	0.000162	0.000857	CcSEcCtD
Lisuride—Orthostatic hypotension—Epirubicin—breast cancer	0.000162	0.000855	CcSEcCtD
Lisuride—Insomnia—Fluorouracil—breast cancer	0.000162	0.000855	CcSEcCtD
Lisuride—Somnolence—Gemcitabine—breast cancer	0.000162	0.000855	CcSEcCtD
Lisuride—Gastrointestinal disorder—Irinotecan—breast cancer	0.000161	0.000852	CcSEcCtD
Lisuride—Fatigue—Mitoxantrone—breast cancer	0.000161	0.000851	CcSEcCtD
Lisuride—Fatigue—Irinotecan—breast cancer	0.000161	0.000851	CcSEcCtD
Lisuride—Vomiting—Goserelin—breast cancer	0.000161	0.00085	CcSEcCtD
Lisuride—Constipation—Mitoxantrone—breast cancer	0.00016	0.000844	CcSEcCtD
Lisuride—Constipation—Irinotecan—breast cancer	0.00016	0.000844	CcSEcCtD
Lisuride—Angiopathy—Capecitabine—breast cancer	0.00016	0.000844	CcSEcCtD
Lisuride—Dyspnoea—Fluorouracil—breast cancer	0.00016	0.000843	CcSEcCtD
Lisuride—Mental disorder—Docetaxel—breast cancer	0.000159	0.000842	CcSEcCtD
Lisuride—Somnolence—Fluorouracil—breast cancer	0.000159	0.000841	CcSEcCtD
Lisuride—Immune system disorder—Capecitabine—breast cancer	0.000159	0.00084	CcSEcCtD
Lisuride—Mediastinal disorder—Capecitabine—breast cancer	0.000159	0.000838	CcSEcCtD
Lisuride—Headache—Goserelin—breast cancer	0.000159	0.000837	CcSEcCtD
Lisuride—Anxiety—Paclitaxel—breast cancer	0.000158	0.000837	CcSEcCtD
Lisuride—Malnutrition—Docetaxel—breast cancer	0.000158	0.000836	CcSEcCtD
Lisuride—Decreased appetite—Gemcitabine—breast cancer	0.000158	0.000836	CcSEcCtD
Lisuride—ADRA2A—female reproductive system—breast cancer	0.000158	0.0133	CbGeAlD
Lisuride—Gastrointestinal disorder—Gemcitabine—breast cancer	0.000157	0.00083	CcSEcCtD
Lisuride—Abdominal discomfort—Methotrexate—breast cancer	0.000157	0.000829	CcSEcCtD
Lisuride—Fatigue—Gemcitabine—breast cancer	0.000157	0.000829	CcSEcCtD
Lisuride—Constipation—Gemcitabine—breast cancer	0.000156	0.000822	CcSEcCtD
Lisuride—Decreased appetite—Fluorouracil—breast cancer	0.000156	0.000822	CcSEcCtD
Lisuride—Dry mouth—Paclitaxel—breast cancer	0.000156	0.000821	CcSEcCtD
Lisuride—Asthenia—Thiotepa—breast cancer	0.000155	0.00082	CcSEcCtD
Lisuride—Gastrointestinal disorder—Fluorouracil—breast cancer	0.000155	0.000816	CcSEcCtD
Lisuride—Mental disorder—Capecitabine—breast cancer	0.000154	0.000815	CcSEcCtD
Lisuride—Feeling abnormal—Irinotecan—breast cancer	0.000154	0.000814	CcSEcCtD
Lisuride—Feeling abnormal—Mitoxantrone—breast cancer	0.000154	0.000814	CcSEcCtD
Lisuride—ADRA2A—adrenal gland—breast cancer	0.000154	0.013	CbGeAlD
Lisuride—Confusional state—Paclitaxel—breast cancer	0.000154	0.000812	CcSEcCtD
Lisuride—Malnutrition—Capecitabine—breast cancer	0.000153	0.00081	CcSEcCtD
Lisuride—Dehydration—Doxorubicin—breast cancer	0.000153	0.000806	CcSEcCtD
Lisuride—Infection—Paclitaxel—breast cancer	0.000151	0.0008	CcSEcCtD
Lisuride—Feeling abnormal—Gemcitabine—breast cancer	0.00015	0.000793	CcSEcCtD
Lisuride—Dizziness—Vinorelbine—breast cancer	0.00015	0.000792	CcSEcCtD
Lisuride—Orthostatic hypotension—Doxorubicin—breast cancer	0.00015	0.000791	CcSEcCtD
Lisuride—Nervous system disorder—Paclitaxel—breast cancer	0.00015	0.00079	CcSEcCtD
Lisuride—Tachycardia—Paclitaxel—breast cancer	0.000149	0.000786	CcSEcCtD
Lisuride—Feeling abnormal—Fluorouracil—breast cancer	0.000148	0.000779	CcSEcCtD
Lisuride—Hyperhidrosis—Paclitaxel—breast cancer	0.000147	0.000778	CcSEcCtD
Lisuride—HTR2B—lymph node—breast cancer	0.000147	0.0124	CbGeAlD
Lisuride—HTR2A—pituitary gland—breast cancer	0.000147	0.0124	CbGeAlD
Lisuride—Anorexia—Paclitaxel—breast cancer	0.000145	0.000768	CcSEcCtD
Lisuride—Vomiting—Vinorelbine—breast cancer	0.000144	0.000761	CcSEcCtD
Lisuride—ADRA2A—female gonad—breast cancer	0.000144	0.0121	CbGeAlD
Lisuride—Dizziness—Thiotepa—breast cancer	0.000143	0.000756	CcSEcCtD
Lisuride—Headache—Vinorelbine—breast cancer	0.000142	0.00075	CcSEcCtD
Lisuride—Syncope—Docetaxel—breast cancer	0.000142	0.00075	CcSEcCtD
Lisuride—Sweating—Methotrexate—breast cancer	0.00014	0.000739	CcSEcCtD
Lisuride—Palpitations—Docetaxel—breast cancer	0.00014	0.000739	CcSEcCtD
Lisuride—Weight increased—Epirubicin—breast cancer	0.000139	0.000737	CcSEcCtD
Lisuride—Weight decreased—Epirubicin—breast cancer	0.000139	0.000732	CcSEcCtD
Lisuride—Cough—Docetaxel—breast cancer	0.000138	0.00073	CcSEcCtD
Lisuride—Insomnia—Paclitaxel—breast cancer	0.000138	0.000728	CcSEcCtD
Lisuride—Vertigo—Capecitabine—breast cancer	0.000138	0.000727	CcSEcCtD
Lisuride—Vomiting—Thiotepa—breast cancer	0.000138	0.000727	CcSEcCtD
Lisuride—Syncope—Capecitabine—breast cancer	0.000137	0.000726	CcSEcCtD
Lisuride—Dyspnoea—Paclitaxel—breast cancer	0.000136	0.000718	CcSEcCtD
Lisuride—Headache—Thiotepa—breast cancer	0.000136	0.000716	CcSEcCtD
Lisuride—Somnolence—Paclitaxel—breast cancer	0.000136	0.000716	CcSEcCtD
Lisuride—Palpitations—Capecitabine—breast cancer	0.000135	0.000715	CcSEcCtD
Lisuride—HTR2A—female reproductive system—breast cancer	0.000134	0.0114	CbGeAlD
Lisuride—Asthenia—Mitoxantrone—breast cancer	0.000134	0.000708	CcSEcCtD
Lisuride—Asthenia—Irinotecan—breast cancer	0.000134	0.000708	CcSEcCtD
Lisuride—Cough—Capecitabine—breast cancer	0.000134	0.000706	CcSEcCtD
Lisuride—ADRA2A—endocrine gland—breast cancer	0.000134	0.0113	CbGeAlD
Lisuride—Decreased appetite—Paclitaxel—breast cancer	0.000133	0.0007	CcSEcCtD
Lisuride—Dry mouth—Docetaxel—breast cancer	0.000132	0.000696	CcSEcCtD
Lisuride—Gastrointestinal disorder—Paclitaxel—breast cancer	0.000132	0.000695	CcSEcCtD
Lisuride—Fatigue—Paclitaxel—breast cancer	0.000131	0.000694	CcSEcCtD
Lisuride—Sweating—Epirubicin—breast cancer	0.000131	0.000692	CcSEcCtD
Lisuride—HTR2A—adrenal gland—breast cancer	0.000131	0.0111	CbGeAlD
Lisuride—Asthenia—Gemcitabine—breast cancer	0.000131	0.00069	CcSEcCtD
Lisuride—Constipation—Paclitaxel—breast cancer	0.00013	0.000689	CcSEcCtD
Lisuride—Confusional state—Docetaxel—breast cancer	0.00013	0.000688	CcSEcCtD
Lisuride—Anxiety—Capecitabine—breast cancer	0.00013	0.000687	CcSEcCtD
Lisuride—Weight increased—Doxorubicin—breast cancer	0.000129	0.000682	CcSEcCtD
Lisuride—Infection—Docetaxel—breast cancer	0.000128	0.000678	CcSEcCtD
Lisuride—Weight decreased—Doxorubicin—breast cancer	0.000128	0.000678	CcSEcCtD
Lisuride—Dry mouth—Capecitabine—breast cancer	0.000128	0.000674	CcSEcCtD
Lisuride—Nervous system disorder—Docetaxel—breast cancer	0.000127	0.000669	CcSEcCtD
Lisuride—Confusional state—Capecitabine—breast cancer	0.000126	0.000666	CcSEcCtD
Lisuride—Tachycardia—Docetaxel—breast cancer	0.000126	0.000666	CcSEcCtD
Lisuride—Feeling abnormal—Paclitaxel—breast cancer	0.000126	0.000664	CcSEcCtD
Lisuride—Infection—Capecitabine—breast cancer	0.000124	0.000656	CcSEcCtD
Lisuride—CYP3A4—female reproductive system—breast cancer	0.000124	0.0105	CbGeAlD
Lisuride—Dizziness—Irinotecan—breast cancer	0.000124	0.000653	CcSEcCtD
Lisuride—Anorexia—Docetaxel—breast cancer	0.000123	0.000651	CcSEcCtD
Lisuride—Nervous system disorder—Capecitabine—breast cancer	0.000123	0.000648	CcSEcCtD
Lisuride—CYP2D6—female reproductive system—breast cancer	0.000122	0.0103	CbGeAlD
Lisuride—Tachycardia—Capecitabine—breast cancer	0.000122	0.000645	CcSEcCtD
Lisuride—Cardiac disorder—Methotrexate—breast cancer	0.000122	0.000643	CcSEcCtD
Lisuride—Sweating—Doxorubicin—breast cancer	0.000121	0.00064	CcSEcCtD
Lisuride—Hyperhidrosis—Capecitabine—breast cancer	0.000121	0.000639	CcSEcCtD
Lisuride—Oedema peripheral—Epirubicin—breast cancer	0.000121	0.000638	CcSEcCtD
Lisuride—Anorexia—Capecitabine—breast cancer	0.000119	0.00063	CcSEcCtD
Lisuride—Angiopathy—Methotrexate—breast cancer	0.000119	0.000628	CcSEcCtD
Lisuride—Vomiting—Irinotecan—breast cancer	0.000119	0.000628	CcSEcCtD
Lisuride—Vomiting—Mitoxantrone—breast cancer	0.000119	0.000628	CcSEcCtD
Lisuride—Immune system disorder—Methotrexate—breast cancer	0.000118	0.000625	CcSEcCtD
Lisuride—Dizziness—Fluorouracil—breast cancer	0.000118	0.000625	CcSEcCtD
Lisuride—Mediastinal disorder—Methotrexate—breast cancer	0.000118	0.000624	CcSEcCtD
Lisuride—Headache—Irinotecan—breast cancer	0.000117	0.000618	CcSEcCtD
Lisuride—Headache—Mitoxantrone—breast cancer	0.000117	0.000618	CcSEcCtD
Lisuride—Insomnia—Docetaxel—breast cancer	0.000117	0.000617	CcSEcCtD
Lisuride—Vomiting—Gemcitabine—breast cancer	0.000116	0.000611	CcSEcCtD
Lisuride—ADRA2C—lymph node—breast cancer	0.000116	0.00979	CbGeAlD
Lisuride—Dyspnoea—Docetaxel—breast cancer	0.000115	0.000608	CcSEcCtD
Lisuride—Somnolence—Docetaxel—breast cancer	0.000115	0.000607	CcSEcCtD
Lisuride—Mental disorder—Methotrexate—breast cancer	0.000115	0.000607	CcSEcCtD
Lisuride—Malnutrition—Methotrexate—breast cancer	0.000114	0.000603	CcSEcCtD
Lisuride—Headache—Gemcitabine—breast cancer	0.000114	0.000602	CcSEcCtD
Lisuride—Cardiac disorder—Epirubicin—breast cancer	0.000114	0.000601	CcSEcCtD
Lisuride—Vomiting—Fluorouracil—breast cancer	0.000114	0.000601	CcSEcCtD
Lisuride—HTR2A—endocrine gland—breast cancer	0.000114	0.00961	CbGeAlD
Lisuride—Insomnia—Capecitabine—breast cancer	0.000113	0.000598	CcSEcCtD
Lisuride—Decreased appetite—Docetaxel—breast cancer	0.000112	0.000593	CcSEcCtD
Lisuride—Headache—Fluorouracil—breast cancer	0.000112	0.000592	CcSEcCtD
Lisuride—Oedema peripheral—Doxorubicin—breast cancer	0.000112	0.000591	CcSEcCtD
Lisuride—Gastrointestinal disorder—Docetaxel—breast cancer	0.000112	0.000589	CcSEcCtD
Lisuride—Dyspnoea—Capecitabine—breast cancer	0.000112	0.000589	CcSEcCtD
Lisuride—Fatigue—Docetaxel—breast cancer	0.000111	0.000588	CcSEcCtD
Lisuride—Angiopathy—Epirubicin—breast cancer	0.000111	0.000588	CcSEcCtD
Lisuride—CYP2D6—female gonad—breast cancer	0.000111	0.00941	CbGeAlD
Lisuride—Immune system disorder—Epirubicin—breast cancer	0.000111	0.000585	CcSEcCtD
Lisuride—Mediastinal disorder—Epirubicin—breast cancer	0.000111	0.000584	CcSEcCtD
Lisuride—Constipation—Docetaxel—breast cancer	0.000111	0.000584	CcSEcCtD
Lisuride—Asthenia—Paclitaxel—breast cancer	0.000109	0.000578	CcSEcCtD
Lisuride—Decreased appetite—Capecitabine—breast cancer	0.000109	0.000574	CcSEcCtD
Lisuride—Gastrointestinal disorder—Capecitabine—breast cancer	0.000108	0.00057	CcSEcCtD
Lisuride—Fatigue—Capecitabine—breast cancer	0.000108	0.00057	CcSEcCtD
Lisuride—Mental disorder—Epirubicin—breast cancer	0.000107	0.000568	CcSEcCtD
Lisuride—Constipation—Capecitabine—breast cancer	0.000107	0.000565	CcSEcCtD
Lisuride—Malnutrition—Epirubicin—breast cancer	0.000107	0.000564	CcSEcCtD
Lisuride—Feeling abnormal—Docetaxel—breast cancer	0.000106	0.000562	CcSEcCtD
Lisuride—Cardiac disorder—Doxorubicin—breast cancer	0.000105	0.000556	CcSEcCtD
Lisuride—CYP3A4—endocrine gland—breast cancer	0.000105	0.00889	CbGeAlD
Lisuride—CYP2D6—endocrine gland—breast cancer	0.000103	0.00875	CbGeAlD
Lisuride—Feeling abnormal—Capecitabine—breast cancer	0.000103	0.000545	CcSEcCtD
Lisuride—Angiopathy—Doxorubicin—breast cancer	0.000103	0.000544	CcSEcCtD
Lisuride—Immune system disorder—Doxorubicin—breast cancer	0.000103	0.000542	CcSEcCtD
Lisuride—Vertigo—Methotrexate—breast cancer	0.000103	0.000541	CcSEcCtD
Lisuride—Mediastinal disorder—Doxorubicin—breast cancer	0.000102	0.00054	CcSEcCtD
Lisuride—Dizziness—Paclitaxel—breast cancer	0.000101	0.000532	CcSEcCtD
Lisuride—Cough—Methotrexate—breast cancer	9.96e-05	0.000526	CcSEcCtD
Lisuride—Mental disorder—Doxorubicin—breast cancer	9.95e-05	0.000525	CcSEcCtD
Lisuride—Malnutrition—Doxorubicin—breast cancer	9.88e-05	0.000522	CcSEcCtD
Lisuride—Vomiting—Paclitaxel—breast cancer	9.69e-05	0.000512	CcSEcCtD
Lisuride—Vertigo—Epirubicin—breast cancer	9.6e-05	0.000507	CcSEcCtD
Lisuride—Syncope—Epirubicin—breast cancer	9.58e-05	0.000506	CcSEcCtD
Lisuride—Headache—Paclitaxel—breast cancer	9.55e-05	0.000504	CcSEcCtD
Lisuride—Palpitations—Epirubicin—breast cancer	9.44e-05	0.000498	CcSEcCtD
Lisuride—Confusional state—Methotrexate—breast cancer	9.39e-05	0.000496	CcSEcCtD
Lisuride—Cough—Epirubicin—breast cancer	9.32e-05	0.000492	CcSEcCtD
Lisuride—Asthenia—Docetaxel—breast cancer	9.27e-05	0.00049	CcSEcCtD
Lisuride—Infection—Methotrexate—breast cancer	9.25e-05	0.000489	CcSEcCtD
Lisuride—ADRA2A—lymph node—breast cancer	9.23e-05	0.00781	CbGeAlD
Lisuride—Nervous system disorder—Methotrexate—breast cancer	9.13e-05	0.000482	CcSEcCtD
Lisuride—Anxiety—Epirubicin—breast cancer	9.06e-05	0.000479	CcSEcCtD
Lisuride—Hyperhidrosis—Methotrexate—breast cancer	9e-05	0.000476	CcSEcCtD
Lisuride—Asthenia—Capecitabine—breast cancer	8.98e-05	0.000474	CcSEcCtD
Lisuride—Dry mouth—Epirubicin—breast cancer	8.89e-05	0.00047	CcSEcCtD
Lisuride—Vertigo—Doxorubicin—breast cancer	8.88e-05	0.000469	CcSEcCtD
Lisuride—Anorexia—Methotrexate—breast cancer	8.88e-05	0.000469	CcSEcCtD
Lisuride—Syncope—Doxorubicin—breast cancer	8.86e-05	0.000468	CcSEcCtD
Lisuride—Confusional state—Epirubicin—breast cancer	8.79e-05	0.000464	CcSEcCtD
Lisuride—Palpitations—Doxorubicin—breast cancer	8.73e-05	0.000461	CcSEcCtD
Lisuride—Infection—Epirubicin—breast cancer	8.66e-05	0.000457	CcSEcCtD
Lisuride—Cough—Doxorubicin—breast cancer	8.62e-05	0.000455	CcSEcCtD
Lisuride—Nervous system disorder—Epirubicin—breast cancer	8.55e-05	0.000451	CcSEcCtD
Lisuride—Dizziness—Docetaxel—breast cancer	8.55e-05	0.000451	CcSEcCtD
Lisuride—Tachycardia—Epirubicin—breast cancer	8.51e-05	0.000449	CcSEcCtD
Lisuride—Hyperhidrosis—Epirubicin—breast cancer	8.43e-05	0.000445	CcSEcCtD
Lisuride—Insomnia—Methotrexate—breast cancer	8.42e-05	0.000445	CcSEcCtD
Lisuride—Anxiety—Doxorubicin—breast cancer	8.38e-05	0.000443	CcSEcCtD
Lisuride—Anorexia—Epirubicin—breast cancer	8.31e-05	0.000439	CcSEcCtD
Lisuride—Dyspnoea—Methotrexate—breast cancer	8.3e-05	0.000439	CcSEcCtD
Lisuride—Somnolence—Methotrexate—breast cancer	8.28e-05	0.000437	CcSEcCtD
Lisuride—Dizziness—Capecitabine—breast cancer	8.27e-05	0.000437	CcSEcCtD
Lisuride—Dry mouth—Doxorubicin—breast cancer	8.23e-05	0.000435	CcSEcCtD
Lisuride—Vomiting—Docetaxel—breast cancer	8.22e-05	0.000434	CcSEcCtD
Lisuride—Confusional state—Doxorubicin—breast cancer	8.13e-05	0.000429	CcSEcCtD
Lisuride—Decreased appetite—Methotrexate—breast cancer	8.1e-05	0.000428	CcSEcCtD
Lisuride—Headache—Docetaxel—breast cancer	8.1e-05	0.000428	CcSEcCtD
Lisuride—Gastrointestinal disorder—Methotrexate—breast cancer	8.04e-05	0.000425	CcSEcCtD
Lisuride—Fatigue—Methotrexate—breast cancer	8.03e-05	0.000424	CcSEcCtD
Lisuride—Infection—Doxorubicin—breast cancer	8.01e-05	0.000423	CcSEcCtD
Lisuride—Vomiting—Capecitabine—breast cancer	7.96e-05	0.00042	CcSEcCtD
Lisuride—Nervous system disorder—Doxorubicin—breast cancer	7.91e-05	0.000418	CcSEcCtD
Lisuride—Insomnia—Epirubicin—breast cancer	7.88e-05	0.000416	CcSEcCtD
Lisuride—Tachycardia—Doxorubicin—breast cancer	7.87e-05	0.000416	CcSEcCtD
Lisuride—Headache—Capecitabine—breast cancer	7.84e-05	0.000414	CcSEcCtD
Lisuride—Hyperhidrosis—Doxorubicin—breast cancer	7.8e-05	0.000412	CcSEcCtD
Lisuride—Dyspnoea—Epirubicin—breast cancer	7.77e-05	0.00041	CcSEcCtD
Lisuride—Somnolence—Epirubicin—breast cancer	7.75e-05	0.000409	CcSEcCtD
Lisuride—Anorexia—Doxorubicin—breast cancer	7.69e-05	0.000406	CcSEcCtD
Lisuride—Feeling abnormal—Methotrexate—breast cancer	7.68e-05	0.000405	CcSEcCtD
Lisuride—Decreased appetite—Epirubicin—breast cancer	7.58e-05	0.0004	CcSEcCtD
Lisuride—Gastrointestinal disorder—Epirubicin—breast cancer	7.53e-05	0.000397	CcSEcCtD
Lisuride—Fatigue—Epirubicin—breast cancer	7.51e-05	0.000397	CcSEcCtD
Lisuride—Constipation—Epirubicin—breast cancer	7.45e-05	0.000394	CcSEcCtD
Lisuride—Insomnia—Doxorubicin—breast cancer	7.29e-05	0.000385	CcSEcCtD
Lisuride—Dyspnoea—Doxorubicin—breast cancer	7.19e-05	0.00038	CcSEcCtD
Lisuride—Feeling abnormal—Epirubicin—breast cancer	7.18e-05	0.000379	CcSEcCtD
Lisuride—Somnolence—Doxorubicin—breast cancer	7.17e-05	0.000379	CcSEcCtD
Lisuride—Decreased appetite—Doxorubicin—breast cancer	7.01e-05	0.00037	CcSEcCtD
Lisuride—Gastrointestinal disorder—Doxorubicin—breast cancer	6.96e-05	0.000368	CcSEcCtD
Lisuride—Fatigue—Doxorubicin—breast cancer	6.95e-05	0.000367	CcSEcCtD
Lisuride—Constipation—Doxorubicin—breast cancer	6.9e-05	0.000364	CcSEcCtD
Lisuride—Asthenia—Methotrexate—breast cancer	6.68e-05	0.000353	CcSEcCtD
Lisuride—Feeling abnormal—Doxorubicin—breast cancer	6.65e-05	0.000351	CcSEcCtD
Lisuride—Asthenia—Epirubicin—breast cancer	6.25e-05	0.00033	CcSEcCtD
Lisuride—Dizziness—Methotrexate—breast cancer	6.16e-05	0.000325	CcSEcCtD
Lisuride—Vomiting—Methotrexate—breast cancer	5.92e-05	0.000313	CcSEcCtD
Lisuride—Headache—Methotrexate—breast cancer	5.83e-05	0.000308	CcSEcCtD
Lisuride—Asthenia—Doxorubicin—breast cancer	5.79e-05	0.000306	CcSEcCtD
Lisuride—Dizziness—Epirubicin—breast cancer	5.76e-05	0.000304	CcSEcCtD
Lisuride—Vomiting—Epirubicin—breast cancer	5.54e-05	0.000293	CcSEcCtD
Lisuride—Headache—Epirubicin—breast cancer	5.46e-05	0.000288	CcSEcCtD
Lisuride—Dizziness—Doxorubicin—breast cancer	5.33e-05	0.000282	CcSEcCtD
Lisuride—Vomiting—Doxorubicin—breast cancer	5.13e-05	0.000271	CcSEcCtD
Lisuride—Headache—Doxorubicin—breast cancer	5.05e-05	0.000267	CcSEcCtD
Lisuride—DRD3—Signaling Pathways—MYC—breast cancer	2.6e-06	2.01e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—CDKN1B—breast cancer	2.6e-06	2.01e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—PTEN—breast cancer	2.6e-06	2.01e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—TGFB1—breast cancer	2.6e-06	2.01e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—TGFB1—breast cancer	2.6e-06	2.01e-05	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—KRAS—breast cancer	2.58e-06	2e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—MAPK8—breast cancer	2.58e-06	2e-05	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—PIK3CA—breast cancer	2.58e-06	2e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—EGFR—breast cancer	2.58e-06	2e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—VEGFA—breast cancer	2.58e-06	2e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling by GPCR—AKT1—breast cancer	2.58e-06	1.99e-05	CbGpPWpGaD
Lisuride—DRD2—GPCR downstream signaling—AKT1—breast cancer	2.58e-06	1.99e-05	CbGpPWpGaD
Lisuride—ADRA2A—Metabolism—PTEN—breast cancer	2.57e-06	1.99e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling by GPCR—PIK3CA—breast cancer	2.56e-06	1.98e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—CDKN1B—breast cancer	2.56e-06	1.98e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—VEGFA—breast cancer	2.55e-06	1.98e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—STAT3—breast cancer	2.55e-06	1.98e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—MDM2—breast cancer	2.55e-06	1.98e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—CASP3—breast cancer	2.55e-06	1.97e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—IL2—breast cancer	2.55e-06	1.97e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—EGFR—breast cancer	2.55e-06	1.97e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—EGFR—breast cancer	2.55e-06	1.97e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—MAPK8—breast cancer	2.54e-06	1.97e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—RAF1—breast cancer	2.54e-06	1.97e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling by GPCR—AKT1—breast cancer	2.54e-06	1.96e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling by GPCR—IL6—breast cancer	2.53e-06	1.96e-05	CbGpPWpGaD
Lisuride—HTR2A—GPCR downstream signaling—AKT1—breast cancer	2.53e-06	1.96e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—RELA—breast cancer	2.53e-06	1.96e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—SRC—breast cancer	2.53e-06	1.96e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—STAT3—breast cancer	2.53e-06	1.96e-05	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—PIK3CA—breast cancer	2.53e-06	1.96e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—PIK3CG—breast cancer	2.53e-06	1.95e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—SRC—breast cancer	2.52e-06	1.95e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—ERBB2—breast cancer	2.52e-06	1.95e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—CASP3—breast cancer	2.51e-06	1.94e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—IL2—breast cancer	2.51e-06	1.94e-05	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—TP53—breast cancer	2.5e-06	1.93e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling by GPCR—IL6—breast cancer	2.49e-06	1.93e-05	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—PIK3CA—breast cancer	2.49e-06	1.93e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—CCND1—breast cancer	2.48e-06	1.92e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—MTOR—breast cancer	2.48e-06	1.92e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—PIK3CB—breast cancer	2.48e-06	1.92e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—JUN—breast cancer	2.48e-06	1.92e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—VEGFA—breast cancer	2.47e-06	1.91e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—CTNNB1—breast cancer	2.46e-06	1.9e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—VEGFA—breast cancer	2.45e-06	1.9e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—SRC—breast cancer	2.45e-06	1.9e-05	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—TP53—breast cancer	2.45e-06	1.89e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—CCND1—breast cancer	2.44e-06	1.89e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—STAT3—breast cancer	2.44e-06	1.89e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—MAPK3—breast cancer	2.44e-06	1.89e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—JUN—breast cancer	2.44e-06	1.89e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—KRAS—breast cancer	2.44e-06	1.89e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—COMT—breast cancer	2.43e-06	1.88e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—STAT3—breast cancer	2.43e-06	1.88e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—CTNNB1—breast cancer	2.42e-06	1.87e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—GSTP1—breast cancer	2.42e-06	1.87e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—MAPK3—breast cancer	2.42e-06	1.87e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—SRC—breast cancer	2.41e-06	1.87e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—MMP9—breast cancer	2.41e-06	1.87e-05	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—TP53—breast cancer	2.41e-06	1.86e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—KRAS—breast cancer	2.41e-06	1.86e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—KRAS—breast cancer	2.41e-06	1.86e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—CDKN1A—breast cancer	2.4e-06	1.86e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—PTEN—breast cancer	2.4e-06	1.86e-05	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—HRAS—breast cancer	2.39e-06	1.85e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—HMOX1—breast cancer	2.39e-06	1.85e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—CXCL8—breast cancer	2.39e-06	1.85e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—VEGFA—breast cancer	2.39e-06	1.85e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—ITPR1—breast cancer	2.38e-06	1.84e-05	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—PIK3CA—breast cancer	2.37e-06	1.84e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—MMP9—breast cancer	2.37e-06	1.84e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—MYC—breast cancer	2.37e-06	1.84e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling by GPCR—HRAS—breast cancer	2.37e-06	1.83e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—TGFB1—breast cancer	2.37e-06	1.83e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—CDKN1A—breast cancer	2.36e-06	1.83e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—STAT3—breast cancer	2.36e-06	1.83e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—PTEN—breast cancer	2.36e-06	1.83e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—MYC—breast cancer	2.35e-06	1.82e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—VEGFA—breast cancer	2.35e-06	1.82e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—MAPK8—breast cancer	2.34e-06	1.81e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—TGFB1—breast cancer	2.34e-06	1.81e-05	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—HRAS—breast cancer	2.34e-06	1.81e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling by GPCR—AKT1—breast cancer	2.34e-06	1.81e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—MAPK3—breast cancer	2.33e-06	1.81e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—CDKN1B—breast cancer	2.33e-06	1.8e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—STAT3—breast cancer	2.33e-06	1.8e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—MAPK3—breast cancer	2.32e-06	1.8e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—EGFR—breast cancer	2.32e-06	1.8e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—MAPK8—breast cancer	2.31e-06	1.79e-05	CbGpPWpGaD
Lisuride—ADRA2A—GPCR downstream signaling—AKT1—breast cancer	2.31e-06	1.78e-05	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—HRAS—breast cancer	2.3e-06	1.78e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling by GPCR—AKT1—breast cancer	2.3e-06	1.78e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—EGFR—breast cancer	2.3e-06	1.78e-05	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—TP53—breast cancer	2.3e-06	1.78e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—ABCB1—breast cancer	2.29e-06	1.77e-05	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—IL6—breast cancer	2.29e-06	1.77e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—CASP3—breast cancer	2.28e-06	1.77e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—IL2—breast cancer	2.28e-06	1.77e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling by GPCR—IL6—breast cancer	2.27e-06	1.76e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—MYC—breast cancer	2.27e-06	1.76e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—TGFB1—breast cancer	2.26e-06	1.75e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—MAPK3—breast cancer	2.26e-06	1.75e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—MYC—breast cancer	2.26e-06	1.75e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—TGFB1—breast cancer	2.25e-06	1.74e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—TYMS—breast cancer	2.25e-06	1.74e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—PIK3CA—breast cancer	2.24e-06	1.73e-05	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—IL6—breast cancer	2.24e-06	1.73e-05	CbGpPWpGaD
Lisuride—ADRA2C—Metabolism—PIK3CA—breast cancer	2.23e-06	1.73e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—PLA2G4A—breast cancer	2.22e-06	1.72e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—GSTM1—breast cancer	2.22e-06	1.72e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—NCOR1—breast cancer	2.22e-06	1.72e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—CCND1—breast cancer	2.22e-06	1.72e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—SRC—breast cancer	2.22e-06	1.72e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—MAPK3—breast cancer	2.22e-06	1.72e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—PIK3CD—breast cancer	2.22e-06	1.72e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—EGFR—breast cancer	2.22e-06	1.72e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—JUN—breast cancer	2.22e-06	1.72e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—PIK3CA—breast cancer	2.21e-06	1.71e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—PIK3CA—breast cancer	2.21e-06	1.71e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—EGFR—breast cancer	2.21e-06	1.71e-05	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—IL6—breast cancer	2.2e-06	1.71e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—CTNNB1—breast cancer	2.2e-06	1.7e-05	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—HRAS—breast cancer	2.2e-06	1.7e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—MYC—breast cancer	2.2e-06	1.7e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—KRAS—breast cancer	2.19e-06	1.7e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—ALB—breast cancer	2.19e-06	1.7e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—TGFB1—breast cancer	2.19e-06	1.7e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—SRC—breast cancer	2.19e-06	1.69e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—KRAS—breast cancer	2.17e-06	1.68e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—TP53—breast cancer	2.17e-06	1.68e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—VEGFA—breast cancer	2.16e-06	1.68e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—MYC—breast cancer	2.16e-06	1.67e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—MMP9—breast cancer	2.16e-06	1.67e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—TGFB1—breast cancer	2.16e-06	1.67e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—CDKN1A—breast cancer	2.15e-06	1.66e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—EGFR—breast cancer	2.15e-06	1.66e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—PTEN—breast cancer	2.15e-06	1.66e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—STAT3—breast cancer	2.14e-06	1.66e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—TP53—breast cancer	2.14e-06	1.65e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—TP53—breast cancer	2.14e-06	1.65e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—VEGFA—breast cancer	2.13e-06	1.65e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—GPX1—breast cancer	2.13e-06	1.65e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—EGFR—breast cancer	2.11e-06	1.64e-05	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—AKT1—breast cancer	2.11e-06	1.63e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—STAT3—breast cancer	2.11e-06	1.63e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—CYP1A1—breast cancer	2.11e-06	1.63e-05	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—IL6—breast cancer	2.1e-06	1.63e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—MAPK8—breast cancer	2.1e-06	1.62e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—NOS3—breast cancer	2.1e-06	1.62e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—KRAS—breast cancer	2.1e-06	1.62e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling by GPCR—AKT1—breast cancer	2.09e-06	1.62e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—ERCC2—breast cancer	2.09e-06	1.62e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—KRAS—breast cancer	2.09e-06	1.61e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—HRAS—breast cancer	2.07e-06	1.6e-05	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—AKT1—breast cancer	2.07e-06	1.6e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—MAPK3—breast cancer	2.05e-06	1.59e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—HRAS—breast cancer	2.04e-06	1.58e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—HRAS—breast cancer	2.04e-06	1.58e-05	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—AKT1—breast cancer	2.03e-06	1.57e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—KRAS—breast cancer	2.03e-06	1.57e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—MAPK3—breast cancer	2.02e-06	1.56e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—PIK3CA—breast cancer	2.01e-06	1.56e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—KRAS—breast cancer	2e-06	1.55e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—PIK3CA—breast cancer	2e-06	1.54e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—MYC—breast cancer	1.99e-06	1.54e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—SRC—breast cancer	1.99e-06	1.54e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—TGFB1—breast cancer	1.99e-06	1.54e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—IL6—breast cancer	1.98e-06	1.54e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—MTHFR—breast cancer	1.97e-06	1.52e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—MYC—breast cancer	1.96e-06	1.52e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—IL6—breast cancer	1.96e-06	1.51e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—IL6—breast cancer	1.96e-06	1.51e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—TGFB1—breast cancer	1.96e-06	1.51e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—EGFR—breast cancer	1.95e-06	1.51e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—TP53—breast cancer	1.95e-06	1.51e-05	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—AKT1—breast cancer	1.94e-06	1.5e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—VEGFA—breast cancer	1.94e-06	1.5e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—PIK3CB—breast cancer	1.94e-06	1.5e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—TP53—breast cancer	1.93e-06	1.49e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—PIK3CA—breast cancer	1.93e-06	1.49e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—STAT3—breast cancer	1.92e-06	1.49e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—PTGS2—breast cancer	1.92e-06	1.48e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—EGFR—breast cancer	1.92e-06	1.48e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—PIK3CA—breast cancer	1.92e-06	1.48e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—PIK3CA—breast cancer	1.86e-06	1.44e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—TP53—breast cancer	1.86e-06	1.44e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—HRAS—breast cancer	1.86e-06	1.44e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—TP53—breast cancer	1.85e-06	1.43e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—HRAS—breast cancer	1.85e-06	1.43e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—KRAS—breast cancer	1.84e-06	1.42e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—PIK3CA—breast cancer	1.83e-06	1.42e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—MAPK3—breast cancer	1.83e-06	1.42e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—AKT1—breast cancer	1.83e-06	1.42e-05	CbGpPWpGaD
Lisuride—ADRA2C—Metabolism—AKT1—breast cancer	1.82e-06	1.41e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—CAV1—breast cancer	1.81e-06	1.4e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—KRAS—breast cancer	1.81e-06	1.4e-05	CbGpPWpGaD
Lisuride—ADRA2A—Metabolism—PIK3CA—breast cancer	1.81e-06	1.4e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—AKT1—breast cancer	1.81e-06	1.4e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—AKT1—breast cancer	1.81e-06	1.4e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—TP53—breast cancer	1.8e-06	1.4e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—MYC—breast cancer	1.78e-06	1.38e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—IL6—breast cancer	1.78e-06	1.38e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—HRAS—breast cancer	1.78e-06	1.38e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—TGFB1—breast cancer	1.78e-06	1.38e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—TP53—breast cancer	1.77e-06	1.37e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—HRAS—breast cancer	1.77e-06	1.37e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—IL6—breast cancer	1.77e-06	1.37e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—EGFR—breast cancer	1.74e-06	1.35e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—HRAS—breast cancer	1.72e-06	1.33e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—IL6—breast cancer	1.71e-06	1.32e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—HRAS—breast cancer	1.7e-06	1.31e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—IL6—breast cancer	1.7e-06	1.31e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—PIK3CA—breast cancer	1.69e-06	1.31e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—PTEN—breast cancer	1.67e-06	1.29e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—PIK3CA—breast cancer	1.66e-06	1.29e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—PIK3CG—breast cancer	1.65e-06	1.28e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—IL6—breast cancer	1.65e-06	1.28e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—KRAS—breast cancer	1.65e-06	1.28e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—AKT1—breast cancer	1.64e-06	1.27e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—TP53—breast cancer	1.64e-06	1.27e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—AKT1—breast cancer	1.63e-06	1.26e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—IL6—breast cancer	1.62e-06	1.26e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—TP53—breast cancer	1.61e-06	1.25e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—AKT1—breast cancer	1.57e-06	1.22e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—AKT1—breast cancer	1.57e-06	1.21e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—HRAS—breast cancer	1.56e-06	1.21e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—HRAS—breast cancer	1.54e-06	1.19e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—AKT1—breast cancer	1.52e-06	1.18e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—PIK3CA—breast cancer	1.51e-06	1.17e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—AKT1—breast cancer	1.5e-06	1.16e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—IL6—breast cancer	1.5e-06	1.16e-05	CbGpPWpGaD
Lisuride—ADRA2A—Metabolism—AKT1—breast cancer	1.48e-06	1.14e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—IL6—breast cancer	1.47e-06	1.14e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—TP53—breast cancer	1.46e-06	1.13e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—PIK3CD—breast cancer	1.45e-06	1.12e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—ALB—breast cancer	1.43e-06	1.11e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—HRAS—breast cancer	1.4e-06	1.08e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—AKT1—breast cancer	1.38e-06	1.07e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—NOS3—breast cancer	1.37e-06	1.06e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—AKT1—breast cancer	1.36e-06	1.05e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—IL6—breast cancer	1.34e-06	1.04e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—PIK3CB—breast cancer	1.27e-06	9.79e-06	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—PTGS2—breast cancer	1.25e-06	9.7e-06	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—AKT1—breast cancer	1.24e-06	9.57e-06	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—PIK3CA—breast cancer	1.18e-06	9.13e-06	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—PTEN—breast cancer	1.09e-06	8.46e-06	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—AKT1—breast cancer	9.64e-07	7.46e-06	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—PIK3CA—breast cancer	7.71e-07	5.97e-06	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—AKT1—breast cancer	6.3e-07	4.88e-06	CbGpPWpGaD
